Whole-exome sequencing of cervical cancer in a Chinese cohort reveals heterogeneous mutational signatures and predicted neoantigens
Frontiers in Oncology · 20.11.2026 · 16
DOI: 10.3389/fonc.2026.1930286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Yibo Li und 2 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Cervical cancer remains a leading cause of cancer-related death among women, and responses to immunotherapy are highly variable. This exploratory study aimed to comprehensively profile the genomic alterations of cervical cancer using paired tumor-normal whole exome sequencing (WES) in a small Chinese cohort.
Methods
We performed WES on paired tumor and adjacent non-tumor tissue specimens from 8 cervical cancer patients treated at a single center in Shenyang, China, who received immunotherapy. Somatic mutations, copy number variations (CNVs), mutational signatures, HLA typing, and neoantigen prediction were systematically analyzed. Functional enrichment analyses were conducted to identify dysregulated biological pathways.
Results
A total of 9,166 somatic mutations were identified across the 8 tumor-normal pairs, with 1,453 high-confidence protein-altering variants retained after stringent quality filtering (variant allele frequency ≥10%, ≥3 supporting reads, and exclusion of recurrent artifacts). The tumor mutational burden (TMB) ranged from 1.3 to 27.0 mutations/Mb (median 3.5), with one hypermutated tumor. Recurrently mutated genes included MUC16 (50%), DNAH9 (50%), and TTN (37.5%). Seven variants were classified as pathogenic or likely pathogenic per ACMG-AMP guidelines, including MSH2 p.R711*, BAX p.M1fs, and FAH p.R174*. COSMIC mutational signature analysis revealed striking heterogeneity: Signature 1A dominated in 5/8 patients, while Signature 3 (associated with homologous recombination deficiency) was prominent in one patient (32.8%), and Signature 15 (associated with mismatch repair deficiency) was detected in another (19.8%). Neoantigen prediction identified 1,746 to 73,212 candidate mutant peptide–HLA class I combinations per patient derived from high-confidence variants, with 18 to 921 strong MHC class I binders. Pathway enrichment analysis highlighted oxytocin signaling, colorectal cancer, and axon guidance pathways concentrated in the hypermutated tumor, with recurrent nominal enrichment of ATP-dependent chromatin remodeling across patients.
Conclusions
This small exploratory study provides a descriptive genomic portrait of cervical cancer in a Chinese cohort, revealing substantial inter-patient mutational heterogeneity. The diverse mutational signatures, variable TMB, and patient-specific neoantigen repertoires observed here are hypothesis-generating and, given the limited sample size, require validation in larger, preferably multi-ethnic cohorts before they can inform personalized immunotherapy strategies for cervical cancer.
Zitieren
APA
Li, Y., Deng, J., & Liu, Y. (2026). Whole-exome sequencing of cervical cancer in a Chinese cohort reveals heterogeneous mutational signatures and predicted neoantigens. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1930286
Vancouver
Li Y, Deng J, Liu Y. Whole-exome sequencing of cervical cancer in a Chinese cohort reveals heterogeneous mutational signatures and predicted neoantigens. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1930286
BibTeX
@article{Li2026,
author = {Li, Yibo and Deng, Jingui and Liu, Yayong},
title = {Whole-exome sequencing of cervical cancer in a Chinese cohort reveals heterogeneous mutational signatures and predicted neoantigens},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1930286}
}
EUVIMED